Key Stats for Cencora Stock
- Past-Week Performance: -6.6%
- 52-Week Range: $265.6 to $377.5
- Current Price: $326.9
What Happened?
Cencora (COR), the U.S. drug distributor processing nearly $86 billion in quarterly revenue, shifted its investment identity on March 17 when CFO James Cleary announced his June 30 retirement, sending shares down 3.4% to $334 and extending the stock’s YTD loss to 1.4% against a 52-week range of $265.59 to $377.54.
Cleary, who joined Cencora in February 2015 after its acquisition of MWI Veterinary Supply and has served as CFO since November 2018, will advise through year-end 2026 while the company runs a parallel internal and external search for his successor.
Cencora simultaneously reaffirmed its FY2026 adjusted diluted EPS guidance of $17.45 to $17.75, bracketing the LSEG consensus of $17.62, and its Q1 adjusted operating income already grew 12% on $85.9 billion in revenue, anchored by 21% U.S. segment growth driven by specialty pharmaceutical sales to health systems and oncology practices.
J.P. Morgan analyst Lisa Gill stated on the March 17 news wire that “his retirement comes as a surprise to us, but with Cleary staying in an advisory capacity through the end of 2026, we think he will be able to work with his successor ahead of providing FY27 guidance in the fall,” directly addressing investor concern over continuity during a year packed with strategic execution.
Cencora enters this leadership transition having raised consolidated operating income guidance twice in six months to 11.5% to 13.5% growth, closed the OneOncology acquisition in February to lift U.S. operating income guidance to 14% to 16%, and executed a $3.5 billion MWI Animal Health divestiture that sharpens the company’s focus on specialty pharmaceutical distribution and its two MSO platforms, Retina Consultants of America and OneOncology.
Wall Street’s Take on COR Stock
Cleary’s June 30 retirement removes the CFO who guided Cencora through both the OneOncology consolidation and the $3.5 billion MWI divestiture, but his advisory role through year-end 2026 preserves continuity precisely when FY2027 guidance is set.
Normalized EPS reached $16.00 in FY2025 and TIKR consensus projects $17.62 in FY2026, rising to $19.64 in FY2027 and $21.79 in FY2028, a trajectory anchored by the U.S. segment’s 14% to 16% operating income growth guidance, itself driven by OneOncology’s full-year contribution.
Twelve of 16 analysts rate COR a buy or outperform, with the mean price target at $410.38 implying 25.5% upside from $326.91, a gap that has widened as the CFO announcement pressured the stock despite a reaffirmed EPS guidance range of $17.45 to $17.75.
The $340.00 low target reflects execution risk during the CFO transition and lingering headwinds from the lost Florida Cancer oncology customer through Q3; the $447.00 high target prices in full OneOncology ramp and accelerating specialty growth into FY2027.
What Does the Valuation Model Say?
The TIKR mid-case target of $461.73 assumes a 6.9% revenue CAGR from $321.3 billion in FY2025 to $452.3 billion by FY2030, with EBITDA margins expanding from 1.5% to 1.7%, powered by the high-margin MSO platform replacing the lower-margin MWI Animal Health revenues.
The market is pricing Cleary’s exit as a structural risk, but Cencora reaffirmed its full $17.45 to $17.75 EPS range on the same announcement, making the 3.4% share drop a mispricing.
The TIKR model’s $461.73 target is justified by normalized EPS compounding at 9.0% annually through FY2030, supported by OneOncology’s full consolidation and the U.S. segment’s raised 14% to 16% operating income growth guidance.
CFO Cleary staying through year-end 2026 in an advisory capacity means the successor will co-author FY2027 guidance, the first clean year reflecting full OneOncology and post-MWI portfolio earnings power.
A successor CFO without Cleary’s eight-year institutional knowledge of Cencora’s specialty contracting and IRA renegotiation mechanics could slow execution on the gross profit dollar protection strategy that underpins FY2026 and FY2027 estimates.
Q2 FY2026 earnings, where OneOncology’s first full quarter of consolidated operating income flows through and interest expense runs at approximately 2x Q1’s $72 million, will confirm whether the 14% to 16% U.S. operating income growth guidance is tracking.
Should You Invest in Cencora, Inc.?
The only way to really know is to look at the numbers yourself. TIKR gives you free access to the same institutional-quality financial data that professional analysts use to answer exactly that question.
Pull up COR stock and you’ll see years of historical financials, what Wall Street analysts expect for revenue and earnings in the quarters ahead, how valuation multiples have moved over time, and whether price targets are trending up or down.
You can build a free watchlist to track Cencora, Inc. alongside every other stock on your radar. No credit card required. Just the data you need to decide for yourself.
Access Professional Tools to Analyze COR stock on TIKR for Free →
